Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OTUD6B-AS1 small interfering RNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral
01
Overview
OTUD6B-AS1 small interfering RNA is an experimental RNA interference (RNAi) agent designed to silence the expression of the long non-coding RNA (lncRNA) OTUD6B-AS1. In the context of cervical cancer, OTUD6B-AS1 is often upregulated and contributes to cisplatin resistance by acting as a molecular sponge for miR-206, which in turn leads to the upregulation of Cyclin D2 (CCND2). By targeting and facilitating the degradation of OTUD6B-AS1 transcripts, this siRNA restores miR-206 levels, reduces CCND2 expression, and sensitizes resistant cancer cells to cisplatin treatment. This approach represents a potential therapeutic strategy for overcoming chemoresistance in gynecological malignancies.
- Other names
- OTUD6B-AS1 siRNAOTUD-6B-AS1 siRNAOTUD 6B-AS1 siRNAsiRNA targeting OTUD6B-AS1
Beyond the preview
Go deeper on OTUD6B-AS1 small interfering RNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OTUD6B-AS1 small interfering RNA.